Purification and Biological Function of Caldecrin
Abstract
:1. Introduction
2. Purification and Cloning of Caldecrin
3. Protein Structure and Protease Activity of Caldecrin
3.1. Structure of Chymotrypsin C (Caldecrin)
3.2. Proteolytic Activity and Specificity of Chymotrypsin C (Caldecrin)
3.3. Chymotrypsin C (Caldecrin) and Pancreatitis
4. Non-Proteolytic Functions of Caldecrin
4.1. Caldecrin and Calcium Metabolism
4.2. Caldecrin and Osteoclast
4.2.1. Caldecrin and RANK Signaling
4.2.2. Caldecrin and TLR4 Signaling
4.2.3. Caldecrin and TREM2 Signaling
4.3. Caldecrin and Inflammation-Related Diseases
4.4. Caldecrin and Muscular Dystrophy
5. Concluding Remarks
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Stewart, A.F.; Longo, W.; Kreutter, D.; Jacob, R.; Burtis, W.J. Hypocalcemia associated with calcium-soap formation in a patient with a pancreatic fistula. N. Engl. J. Med. 1986, 315, 496–498. [Google Scholar] [CrossRef]
- Williams, G.A.; Bowser, E.N.; Henderson, W.J. Mode of hypocalcemic action of glucagon in the rat. Endocrinology 1969, 85, 537–541. [Google Scholar] [CrossRef]
- Stern, P.H.; Bell, N.H. Effects of glucagon on serum calcium in the rat and on bone resorption in tissue culture. Endocrinology 1970, 87, 111–117. [Google Scholar] [CrossRef]
- Zaidi, M.; Datta, H.K.; Bevis, P.J.; Wimalawansa, S.J.; MacIntyre, I. Amylin-amide: A new bone-conserving peptide from the pancreas. Exp. Physiol. 1990, 75, 529–536. [Google Scholar] [CrossRef] [PubMed]
- Alam, A.S.; Moonga, B.S.; Bevis, P.J.; Huang, C.L.; Zaidi, M. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp. Physiol. 1993, 78, 183–196. [Google Scholar] [CrossRef] [PubMed]
- Pettersson, M.; Ahren, B.; Böttcher, G.; Sundler, F. Calcitonin gene-related peptide: Occurrence in pancreatic islets in the mouse and the rat and inhibition of insulin secretion in the mouse. Endocrinology 1986, 119, 865–869. [Google Scholar] [CrossRef]
- D’Souza, S.M.; MacIntyre, I.; Girgis, S.I.; Mundy, G.R. Human synthetic calcitonin gene-related peptide inhibits bone resorption in vitro. Endocrinology 1986, 119, 58–61. [Google Scholar] [CrossRef]
- Tomomura, A.; Fukushige, T.; Noda, T.; Noikura, T.; Saheki, T. Serum calcium-decreasing factor (caldecrin) from porcine pancreas has proteolytic activity which has no clear connection with the calcium decrease. FEBS Lett. 1992, 301, 277–281. [Google Scholar] [CrossRef] [Green Version]
- Tomomura, A.; Fukushige, T.; Tomomura, M.; Noikura, T.; Nishii, Y.; Saheki, T. Caldecrin proform requires trypsin activation for the acquisition of serum calcium-decreasing activity. FEBS Lett. 1993, 335, 213–216. [Google Scholar] [CrossRef] [Green Version]
- Tomomura, A.; Tomomura, M.; Fukushige, T.; Akiyama, M.; Kubota, N.; Kumaki, K.; Nishii, Y.; Noikura, T.; Saheki, T. Molecular cloning and expression of serum calcium-decreasing factor (caldecrin). J. Biol. Chem. 1995, 270, 30315–30321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takaoka, Y.; Hiwaki, C.; Ozawa, H.; Ichinose, M.; Otsubo, Y.; Shikaya, T. A pancreatic protein anabolic extract. Proposal of a protein anabolic extract from pancreas. I. Preliminary report. Acta Med. Nagasaki 1966, 10, 51–57. [Google Scholar]
- Takaoka, Y.; Takamori, M.; Ichinose, M.; Shikaya, T.; Igawa, N. Hypocalcemic action of a pancreatic factor and its clinical significance on the myasthenic patients. Acta Med. Nagasaki 1969, 14, 28–35. [Google Scholar]
- Kang, J.; Wiegand, U.; Müller-Hill, B. Identification of cDNAs encoding two novel rat pancreatic serine proteases. Gene 1992, 110, 181–187. [Google Scholar] [CrossRef]
- Gomis-Rüth, F.X.; Gómez, M.; Bode, W.; Huber, R.; Avilés, F.X. The three-dimensional structure of the native ternary complex of bovine pancreatic procarboxypeptidase A with proproteinase E and chymotrypsinogen C. EMBO J. 1995, 14, 4387–4394. [Google Scholar] [CrossRef] [PubMed]
- Tomomura, A.; Akiyama, M.; Itoh, H.; Yoshino, I.; Tomomura, M.; Nishii, Y.; Noikura, T.; Saheki, T. Molecular cloning and expression of human caldecrin. FEBS Lett. 1996, 386, 26–28. [Google Scholar] [CrossRef] [Green Version]
- Yoshino-Yasuda, I.; Kobayashi, K.; Akiyama, M.; Itoh, H.; Tomomura, A.; Saheki, T. Caldecrin is a novel-type serine protease expressed in pancreas, but its homologue, elastase IV, is an artifact during cloning derived from caldecrin gene. J. Biochem. 1998, 123, 546–554. [Google Scholar] [CrossRef] [PubMed]
- CTRC Chymotrypsin C. Homo Sapiens (Human). Available online: https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/gene/11330 (accessed on 28 May 2021).
- Chymotrypsin C|S1: Chymotrypsin|IUPHAR/BPS Guide to PHARMACOLOGY. Available online: http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2341 (accessed on 28 May 2021).
- Batra, J.; Szabó, A.; Caulfield, T.R.; Soares, A.S.; Sahin-Tóth, M.; Radisky, E.S. Long-range electrostatic complementarity governs substrate recognition by human chymotrypsin C, a key regulator of digestive enzyme activation. J. Biol. Chem. 2013, 288, 9848–9859. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.; Yuan, D.; Xu, R.; Chi, C.-H. Purification, cDNA cloning, and recombinant expression of chymotrypsin C from porcine pancreas. Acta Biochim. Biophys. Sin. 2011, 43, 568–575. [Google Scholar] [CrossRef] [Green Version]
- Chymotrypsin, C. Available online: https://enzyme.expasy.org/EC/3.4.21.2 (accessed on 28 May 2021).
- Pancreatic Elastase II. Available online: https://enzyme.expasy.org/EC/3.4.21.71 (accessed on 28 May 2021).
- Pancreatic Endopeptidase E. Available online: https://enzyme.expasy.org/EC/3.4.21.70 (accessed on 28 May 2021).
- Steer, M.L.; Waxman, I. Chronic pancreatitis. N. Engl. J. Med. 1995, 332, 1482–1490. [Google Scholar] [CrossRef] [PubMed]
- Sahin-Tóth, M. Biochemical models of hereditary pancreatitis. Endocrinol. Metab. Clin. North. Am. 2006, 35, 303–312. [Google Scholar] [CrossRef] [Green Version]
- Teich, N.; Rosendahl, J.; Tóth, M.; Mössner, J.; Sahin-Tóth, M. Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum. Mutat. 2006, 27, 721–730. [Google Scholar] [CrossRef] [Green Version]
- Drenth, J.P.; te Morsche, R.; Jansen, J.B. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. Gut 2002, 50, 687–692. [Google Scholar] [CrossRef]
- Whitcomb, D.C.; Gorry, M.C.; Preston, R.A.; Furey, W.; Sossenheimer, M.J.; Ulrich, C.D.; Martin, S.P.; Gates, L.K., Jr.; Amann, S.T.; Toskes, P.P.; et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat. Genet. 1996, 14, 141–145. [Google Scholar] [CrossRef] [PubMed]
- Várallyay, E.; Pál, G.; Patthy, A.; Szilágyi, L.; Gráf, L. Two mutations in rat trypsin confer resistance against autolysis. Biochem. Biophys. Res. Commun. 1998, 243, 56–60. [Google Scholar] [CrossRef] [PubMed]
- Rinderknecht, H.; Adham, N.F.; Renner, I.G.; Carmack, C. A possible zymogen self-destruct mechanism preventing pancreatic autodigestion. Int. J. Pancreatol. 1988, 3, 33–44. [Google Scholar] [CrossRef]
- Nemoda, Z.; Sahin-Tóth, M. Chymotrypsin C (caldecrin) stimulates autoactivation of human cationic trypsinogen. J. Biol. Chem. 2006, 281, 11879–11886. [Google Scholar] [CrossRef] [Green Version]
- Szmola, R.; Sahin-Tóth, M. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: Identity with Rinderknecht’s enzyme Y. Proc. Natl. Acad. Sci. USA 2007, 104, 11227–11232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosendahl, J.; Witt, H.; Szmola, R.; Bhatia, E.; Ozsvári, B.; Landt, O.; Schulz, H.U.; Gress, T.M.; Pfützer, R.; Löhr, M.; et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat. Genet. 2008, 40, 78–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Masson, E.; Chen, J.M.; Scotet, V.; Le Maréchal, C.; Férec, C. Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis. Hum. Genet. 2008, 123, 83–91. [Google Scholar] [CrossRef]
- Hegyi, E.; Sahin-Tóth, M. Genetic Risk in Chronic Pancreatitis: The Trypsin-Dependent Pathway. Dig. Dis. Sci. 2017, 62, 1692–1701. [Google Scholar] [CrossRef] [PubMed]
- Derikx, M.H.; Szmola, R.; Morsche, R.H.; Sunderasan, S.; Chacko, A.; Drenth, J.P. Tropical calcific pancreatitis and its association with CTRC and SPINK1 (p.N34S) variants. Eur. J. Gastroenterol. Hepatol. 2009, 21, 889–894. [Google Scholar] [CrossRef] [PubMed]
- Paliwal, S.; Bhaskar, S.; Mani, K.R.; Reddy, D.N.; Rao, G.V.; Singh, S.P.; Thomas, V.; Chandak, G.R. Comprehensive screening of chymotrypsin C (CTRC) gene in tropical calcific pancreatitis identifies novel variants. Gut 2013, 62, 1602–1606. [Google Scholar] [CrossRef]
- Nemeth, B.C.; Sahin-Toth, M. Human cationic trypsinogen (PRSS1) variants and chronic pancreatitis. Am. J. Physiol. Gastrointest Liver Physiol. 2014, 306, G466–G473. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Izbicka, E.; Yoneda, T.; Takaoka, Y.; Horn, D.; Williams, P.; Mundy, G.R. Identification of a novel bone/calcium metabolism-regulating factor in porcine pancreas. J. Biol. Chem. 1996, 271, 23230–23234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, B.R.; Rho, J.; Arron, J.; Robinson, E.; Orlinick, J.; Chao, M.; Kalachikov, S.; Cayani, E.; Bartlett, F.S., III; Frankel, W.N.; et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 1997, 272, 25190–25194. [Google Scholar] [CrossRef] [Green Version]
- Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc. Natl. Acad. Sci. USA 1998, 95, 3597–3602. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lacey, D.L.; Timms, E.; Tan, H.L.; Kelley, M.J.; Dunstan, C.R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93, 165–176. [Google Scholar] [CrossRef] [Green Version]
- Fuller, K.; Wong, B.; Fox, S.; Choi, Y.; Chambers, T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 1998, 188, 997–1001. [Google Scholar] [CrossRef]
- Nakashima, T.; Hayashi, M.; Fukunaga, T.; Kurata, K.; Oh-Hora, M.; Feng, J.Q.; Bonewald, L.F.; Kodama, T.; Wutz, A.; Wagner, E.F.; et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 2011, 17, 1231–1234. [Google Scholar] [CrossRef]
- Suda, T.; Takahashi, N.; Martin, T.J. Modulation of osteoclast differentiation. Endocr. Rev. 1992, 13, 66–80. [Google Scholar] [CrossRef]
- Teitelbaum, S.L. Bone resorption by osteoclasts. Science 2000, 289, 1504–1508. [Google Scholar] [CrossRef] [PubMed]
- Asagiri, M.; Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 2007, 40, 251–264. [Google Scholar] [CrossRef] [PubMed]
- Wong, B.R.; Josien, R.; Lee, S.Y.; Vologodskaia, M.; Steinman, R.M.; Choi, Y. The TRAF family of signal transducers mediate NF-kB activation by the TRANCE receptor. J. Biol. Chem. 1998, 273, 28355–28359. [Google Scholar] [CrossRef] [Green Version]
- Mizukami, J.; Takaesu, G.; Akatsuka, H.; Sakurai, H.; Ninomiya-Tsuji, J.; Matsumoto, K.; Sakurai, N. Receptor activator of NF-kB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell Biol. 2002, 22, 992–1000. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Darnay, B.G.; Haridas, V.; Ni, J.; Moore, P.A.; Aggarwal, B.B. Characterization of the intracellular domain of receptor activator of NF-kB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kB and c-Jun N-terminal kinase. J. Biol. Chem. 1998, 273, 20551–20555. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.E.; Woo, K.M.; Kim, S.Y.; Kim, H.M.; Kwack, K.; Lee, Z.H.; Kim, H.H. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002, 30, 71–77. [Google Scholar] [CrossRef]
- Li, X.; Udagawa, N.; Itoh, K.; Suda, K.; Murase, Y.; Nishihara, T.; Suda, T.; Takahashi, N. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002, 43, 3105–3113. [Google Scholar] [CrossRef]
- David, J.P.; Sabapathy, K.; Hoffmann, O.; Idarraga, M.H.; Wagner, E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 2002, 115, 4317–4325. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.Q.; Ovitt, C.; Grigoriadis, A.E.; Mohle-Steinlein, U.; Ruther, U.; Wagner, E.F. Bone and haematopoietic defects in mice lacking c-fos. Nature 1992, 360, 741–745. [Google Scholar] [CrossRef]
- Takayanagi, H.; Kim, S.; Koga, T.; Nishina, H.; Isshiki, M.; Yoshida, H.; Saiura, A.; Isobe, M.; Yokochi, T.; Inoue, J.; et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002, 3, 889–901. [Google Scholar] [CrossRef] [Green Version]
- Ishida, N.; Hayashi, K.; Hoshijima, M.; Ogawa, T.; Koga, S.; Miyatake, Y.; Kumegawa, M.; Kimura, T.; Takeya, T. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 2002, 277, 41147–41156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koga, T.; Inui, M.; Inoue, K.; Kim, S.; Suematsu, A.; Kobayashi, E.; Iwata, T.; Ohnishi, H.; Matozaki, T.; Kodama, T.; et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428, 758–763. [Google Scholar] [CrossRef] [PubMed]
- Mócsai, A.; Humphrey, M.B.; van Ziffle, J.A.G.; Hu, Y.; Burghardt, A.; Spusta, S.C.; Majumdar, S.; Lanier, L.L.; Lowell, C.A.; Nakamura, M.C. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. USA 2004, 101, 6158–6163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asagiri, M.; Sato, K.; Usami, T.; Ochi, S.; Nishina, H.; Yoshida, H.; Morita, I.; Wagner, E.F.; Mak, T.W.; Serfling, E.; et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 2005, 202, 1261–1269. [Google Scholar] [CrossRef] [Green Version]
- Hirotani, H.; Tuohy, N.A.; Woo, J.T.; Stern, P.H.; Clipstone, N.A. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem. 2004, 279, 13984–13992. [Google Scholar] [CrossRef] [Green Version]
- Hasegawa, H.; Kido, S.; Tomomura, M.; Fujimoto, K.; Ohi, M.; Kiyomura, M.; Kanegae, H.; Inaba, A.; Sakagami, H.; Tomomura, A. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity. J. Biol. Chem. 2010, 285, 25448–25457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teti, A.; Marchisio, P.C.; Zallone, A.Z. Clear zone in osteoclast function: Role of podosomes in regulation of bone-resorbing activity. Am. J. Physiol. 1991, 261, C1–C7. [Google Scholar] [CrossRef]
- Zou, W.; Teitelbaum, S.L. Integrins, growth factors, and the osteoclast cytoskeleton. Ann. N. Y. Acad. Sci. 2010, 1192, 27–31. [Google Scholar] [CrossRef]
- Zou, W.; Kitaura, H.; Reeve, J.; Long, F.; Tybulewicz, V.L.; Shattil, S.J.; Ginsberg, M.H.; Ross, F.P.; Teitelbaum, S.L. Syk, c-Src, the avb3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell Biol. 2007, 176, 877–888. [Google Scholar] [CrossRef]
- Reeve, J.L.; Zou, W.; Liu, Y.; Maltzman, J.S.; Ross, F.P.; Teitelbaum, S.L. SLP-76 couples Syk to the osteoclast cytoskeleton. J. Immunol. 2009, 183, 1804–1812. [Google Scholar] [CrossRef] [Green Version]
- Duong, L.T.; Lakkakorpi, P.T.; Nakamura, I.; Machwate, M.; Nagy, R.M.; Rodan, G.A. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J. Clin. Investig. 1998, 102, 881–892. [Google Scholar] [CrossRef] [Green Version]
- Wang, K.Z.; Wara-Aswapati, N.; Boch, J.A.; Yoshida, Y.; Hu, C.D.; Galson, D.L.; Auron, P.E. TRAF6 activation of PI 3-kinase-dependent cytoskeletal changes is cooperative with Ras and is mediated by an interaction with cytoplasmic Src. J. Cell Sci. 2006, 119, 1579–1591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kajiya, H.; Okamoto, F.; Nemoto, T.; Kimachi, K.; Toh-Goto, K.; Nakayana, S.; Okabe, K. RANKL-induced TRPV2 expression regulates osteoclastogenesis via calcium oscillations. Cell Calcium 2010, 48, 260–269. [Google Scholar] [CrossRef] [PubMed]
- Masuyama, R.; Vriens, J.; Voets, T.; Karashima, Y.; Owsianik, G.; Vennekens, R.; Lieben, L.; Torrekens, S.; Moermans, K.; Vanden Bosch, A.; et al. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab. 2008, 8, 257–265. [Google Scholar] [CrossRef] [Green Version]
- Chamoux, E.; Bisson, M.; Payet, M.D.; Roux, S. TRPV-5 mediates a receptor activator of NF-kB (RANK) ligand-induced increase in cytosolic Ca2+ in human osteoclasts and down-regulates bone resorption. J. Biol. Chem. 2010, 285, 25354–25362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomomura, M.; Hasegawa, H.; Suda, N.; Sakagami, H.; Tomomura, A. Serum calcium-decreasing factor, caldecrin, inhibits receptor activator of NF-κB ligand (RANKL)-mediated Ca2+ signaling and actin ring formation in mature osteoclasts via suppression of Src signaling pathway. J. Biol. Chem. 2012, 287, 17963–17974. [Google Scholar] [CrossRef] [Green Version]
- Nair, S.P.; Meghji, S.; Wilson, M.; Reddi, K.; White, P.; Henderson, B. Bacterially induced bone destruction: Mechanisms and misconceptions. Infect. Immun. 1996, 64, 2371–2380. [Google Scholar] [CrossRef] [Green Version]
- Tobias, P.S.; Gegner, J.; Tapping, R.; Orr, S.; Mathison, J.; Lee, J.D.; Kravchenko, V.; Han, J.; Ulevitch, R.J. Lipopolysaccharide dependent cellular activation. J. Periodontal Res. 1997, 32, 99–103. [Google Scholar] [CrossRef]
- Takami, M.; Kim, N.; Rho, J.; Choi, Y. Stimulation by toll-like receptors inhibits osteoclast differentiation. J. Immunol. 2002, 169, 1516–1523. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qureshi, S.T.; Larivière, L.; Leveque, G.; Clermont, S.; Moore, K.J.; Gros, P.; Malo, D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 1999, 189, 615–625. [Google Scholar] [CrossRef] [Green Version]
- Hou, L.; Sasaki, H.; Stashenko, P. Toll-like receptor 4-deficient mice have reduced bone destruction following mixed anaerobic infection. Infect. Immun. 2000, 68, 4681–4687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Satoh, T.; Akira, S. Toll-Like receptor signaling and its inducible proteins. Microbiol. Spectr. 2016, 4. [Google Scholar] [CrossRef]
- Takeda, K.; Akira, S. TLR signaling pathways. Semin Immunol. 2004, 16, 3–9. [Google Scholar] [CrossRef]
- Akira, S.; Takeda, K. Toll-like receptor signaling. Nat. Rev. Immunol. 2004, 4, 499–511. [Google Scholar] [CrossRef] [PubMed]
- Medzhitov, R.; Preston-Hurlburt, P.; Kopp, E.; Stadlen, A.; Chen, C.; Ghosh, S.; Janeway, C.A., Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 1998, 2, 253–258. [Google Scholar] [CrossRef]
- Zou, W.; Bar-Shavit, Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J. Bone Miner. Res. 2002, 17, 1211–1218. [Google Scholar] [CrossRef]
- Liu, J.; Wang, S.; Zhang, P.; Said-Al-Naief, N.; Michalek, S.M.; Feng, X. Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. J. Biol. Chem. 2009, 284, 12512–12523. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Reilly, S.M.; Moynagh, P.N. Regulation of Toll-like receptor 4 signaling by A20 zinc finger protein. Biochem. Biophys. Res. Commun. 2003, 303, 586–593. [Google Scholar] [CrossRef]
- Ingrid, E.; Wertz, I.E.; O’Rourke, K.M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430, 694–699. [Google Scholar] [CrossRef]
- Mabilleau, G.; Chappard, D.; Sabokbar, A. Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J. Biol. Chem. 2011, 286, 3242–3249. [Google Scholar] [CrossRef] [Green Version]
- Hong, J.-Y.; Bae, W.-J.; Yi, J.-K.; Kim, G.-T.; Kim, E.-C. Anti-inflammatory and anti-osteoclastogenic effects of zinc finger protein A20 overexpression in human periodontal ligament cells. J. Periodontal Res. 2016, 51, 529–539. [Google Scholar] [CrossRef] [PubMed]
- Kawaguchi, S.; Bandow, K.; Tamura, N.; Tomomura, M.; Shimada, J.; Tomomura, A. Effect of caldecrin on the lipopolysaccharide-induced osteoclast differentiation. J. Meikai Dent. Med. 2018, 47, 126–138. [Google Scholar]
- Sharif, O.; Knapp, S. From expression to signaling: Roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 2008, 213, 701–713. [Google Scholar] [CrossRef] [PubMed]
- Ford, J.W.; McVicar, D.W. TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol. 2009, 21, 38–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Klesney-Tait, J.; Turnbull, I.R.; Colonna, M. The TREM receptor family and signal integration. Nat. Immunol. 2006, 7, 1266–1273. [Google Scholar] [CrossRef]
- Humphrey, M.B.; Daws, M.R.; Spusta, S.C.; Niemi, E.C.; Torchia, J.A.; Lanier, L.L.; Seaman, W.E.; Nakamura, M.C. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J. Bone Min. Res. 2006, 21, 237–245. [Google Scholar] [CrossRef] [Green Version]
- Kaifu, T.; Nakahara, J.; Inui, M.; Mishima, K.; Momiyama, T.; Kaji, M.; Sugahara, A.; Koito, H.; Ujike-Asai, A.; Nakamura, A.; et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Investig. 2003, 111, 323–332. [Google Scholar] [CrossRef] [Green Version]
- Marco Colonna, M.; Turnbull, I.; Klesney-Tait, J. The enigmatic function of TREM-2 in osteoclastogenesis. Adv. Exp. Med. Biol. 2007, 602, 97–105. [Google Scholar] [CrossRef]
- Otero, K.; Shinohara, M.; Zhao, H.; Cella, M.; Gilfillan, S.; Colucci, A.; Faccio, R.; Ross, F.P.; Teitelbaum, S.L.; Takayanagi, H.; et al. TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J. Immunol. 2012, 188, 2612–2621. [Google Scholar] [CrossRef]
- Mantovani, A.; Sica, A.; Sozzani, S.; Allavena, P.; Vecchi, A.; Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25, 677–686. [Google Scholar] [CrossRef]
- Gordon, S.; Taylor, P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5, 953–964. [Google Scholar] [CrossRef]
- Mills, C.D.; Kincaid, K.; Alt, J.M.; Heilman, M.J.; Hill, A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 2000, 164, 6166–6173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Italiani, P.; Boraschi, D. From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation. Front. Immunol. 2014, 5, 514. [Google Scholar] [CrossRef] [Green Version]
- Turnbull, I.R.; Gilfillan, S.; Cella, M.; Aoshi, T.; Miller, M.; Piccio, L.; Hernandez, M.; Colonna, M. Cutting Edge: TREM-2 Attenuates Macrophage Activation. J. Immunol. 2006, 177, 3520–3524. [Google Scholar] [CrossRef]
- Bandow, K.; Hasegawa, H.; Tomomura, M.; Tomomura, A. Caldecrin inhibits lipopolysaccharide-induced pro-inflammatory cytokines and M1 macrophage polarization through the immunoreceptor triggering receptor expressed in myeloid cells-2. Biochem.Biophys. Res. Commun. 2020, 523, 1027–1033. [Google Scholar] [CrossRef]
- Guo, Q.; Wang, Y.; Xu, D.; Nossent, J.; Pavlos, N.J.; Xu, J. Rheumatoid arthritis: Pathological mechanisms and modern. pharmacologic therapies. Bone Res. 2018, 6, 15. [Google Scholar] [CrossRef] [PubMed]
- Auréal, M.; Machuca-Gayet, I.; Coury, F. Rheumatoid arthritis in the view of osteoimmunology. Biomolecules 2020, 11, 48. [Google Scholar] [CrossRef] [PubMed]
- Sweeney, S.E.; Firestein, G.S. Rheumatoid arthritis: Regulation of synovial inflammation. Int. J. Biochem. Cell Biol. 2004, 36, 372–378. [Google Scholar] [CrossRef]
- Gravallese, E.M.; Manning, C.; Tsay, A.; Naito, A.; Pan, C.; Amento, E.; Goldring, S.R. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43, 250–258. [Google Scholar] [CrossRef]
- Takayanagi, H.; Iizuka, H.; Juji, T.; Nakagawa, T.; Yamamoto, A.; Miyazaki, T.; Koshihara, Y.; Oda, H.; Nakamura, K.; Tanaka, S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000, 43, 259–269. [Google Scholar] [CrossRef]
- Crotti, T.N.; Smith, M.D.; Weedon, H.; Ahern, M.J.; Findlay, D.M.; Kraan, M.; Tak, P.P.; Haynes, D.R. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: Semiquantitative and quantitative analysis. Ann. Rheum. Dis. 2002, 61, 1047–1054. [Google Scholar] [CrossRef] [Green Version]
- Wei, S.; Kitaura, H.; Zhou, P.; Ross, F.P.; Teitelbaum, S.L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Investig. 2005, 115, 282–290. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, T.; He, C. TNF-alpha and IL-6: The Link between Immune and Bone System. Curr. Drug Targets. 2020, 21, 213–227. [Google Scholar] [CrossRef]
- Lam, J.; Takeshita, S.; Barker, J.E.; Kanagawa, O.; Ross, E.P.; Teitelbaum, S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Investig. 2000, 106, 1481–1488. [Google Scholar] [CrossRef]
- Hashizume, M.; Mihara, M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011. [Google Scholar] [CrossRef] [PubMed]
- Elsby, L.M.; Orozco, G.; Denton, J.; Worthington, J.; Ray, D.W.; Donn, R.P. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin. Exp. Rheumatol. 2010, 28, 708–714. [Google Scholar] [PubMed]
- Hah, Y.S.; Lee, Y.R.; Jun, J.S.; Lim, H.S.; Kim, H.O.; Jeong, Y.G.; Hur, G.M.; Lee, S.Y.; Chung, M.J.; Park, J.W.; et al. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 2010, 62, 2313–2321. [Google Scholar] [CrossRef]
- Zhang, L.; Yao, Y.; Tian, J.; Jiang, W.; Zhou, S.; Chen, J.; Xu, T.; Wu, M. Alterations and abnormal expression of A20 in peripheral monocyte subtypes in patients with rheumatoid arthritis. Clin. Rheumatol. 2021, 40, 341–348. [Google Scholar] [CrossRef] [PubMed]
- Fujimoto, K.; Oi, M.; hasegawa, K.; kanegae, H.; Inaba, A.; Tomomura, M.; Tomomura, A. Inhibition of RANKL Expression in Synovial Fibroblasts of Rheumatoid Arthritis by Serum Calcium-decreasing Factor (Caldecrin). J. Meikai Dent. Med. 2010, 39, 42–51. [Google Scholar]
- Manolagas, S.C. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 2000, 21, 115–137. [Google Scholar]
- Weitzmann, M.N.; Pacifici, R. Estrogen deficiency and bone loss: An inflammatory tale. J. Clin. Investig. 2006, 116, 1186–1194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cenci, S.; Weitzmann, M.N.; Roggia, C.; Namba, N.; Novack, D.; Woodring, J.; Pacifici, R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Investig. 2000, 106, 1229–1237. [Google Scholar] [CrossRef]
- Zhao, R. Immune regulation of osteoclast function in postmenopausal osteoporosis: A critical interdisciplinary perspective. Int J. Med. Sci. 2012, 9, 825–832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roggia, C.; Gao, Y.; Cenci, S.; Weitzmann, M.N.; Toraldo, G.; Isaia, G.; Pacifici, R. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 13960–13965. [Google Scholar] [CrossRef] [Green Version]
- Oi, M.; Kido, S.; Hasegawa, H.; Fujimoto, K.; Tomomura, M.; Kanegae, H.; Suda, N.; Tomomura, A. Inhibitory effects on bone resorption in postmenopausal osteoporosis model mice by delivery of serum calcium decreasing factor (Caldecrin) gene. J. Meikai Dent. Med. 2011, 40, 146–154. [Google Scholar]
- Hamel, J.; Tawil, R. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments. Neurotherapeutics 2018, 15, 863–871. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lefkowitz, D.L.; Lefkowitz, S.S. Fascioscapulohumeral muscular dystrophy: A progressive degenerative disease that responds to diltiazem. Med. Hypotheses 2005, 65, 716–721. [Google Scholar] [CrossRef]
- Tomomura, M.; Fujii, T.; Sakagami, H.; Tomomura, A. Serum calcium-decreasing factor, caldecrin, ameliorates muscular dystrophy in dy/dy mice. In Vivo 2011, 25, 157–163. [Google Scholar]
- Lefkowitz, S.S.; Lefkowitz, D.L.; Kethley, J. Treatment of facioscapulohumeral muscular dystrophy with Denosumab. Am. J. Case Rep. 2012, 13, 66–68. [Google Scholar] [CrossRef] [PubMed]
- Hamoudi, D.; Marcadet, L.; Piette Boulanger, A.; Yagita, H.; Bouredji, Z.; Argaw, A.; Frenette, J. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. Hum. Mol. Genet. 2019, 28, 3101–3112. [Google Scholar] [CrossRef] [PubMed]
- Hamoudi, D.; Bouredji, Z.; Marcadet, L.; Yagita, H.; Landry, L.B.; Argaw, A.; Frenette, J. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice. Hum. Mol. Genet. 2020, 29, 483–494. [Google Scholar] [CrossRef] [PubMed]
- Bonnet, N.; Bourgoin, L.; Biver, E.; Douni, E.; Ferrari, S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Investig. 2020, 130, 3329. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tomomura, A.; Bandow, K.; Tomomura, M. Purification and Biological Function of Caldecrin. Medicines 2021, 8, 41. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8080041
Tomomura A, Bandow K, Tomomura M. Purification and Biological Function of Caldecrin. Medicines. 2021; 8(8):41. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8080041
Chicago/Turabian StyleTomomura, Akito, Kenjiro Bandow, and Mineko Tomomura. 2021. "Purification and Biological Function of Caldecrin" Medicines 8, no. 8: 41. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8080041